论文部分内容阅读
目的:回顾性分析利伐沙班抗深静脉血栓形成的临床疗效及安全性。方法:收集本院2010年6月~2013年6月下肢骨手术患者共94例,按使用药品不同分为Ⅰ组(利伐沙班片10 mg,po,qd)和Ⅱ组(低分子肝素注射液4 000 IU,ih,qd)。比较两组术后出血情况,用药前后各项血常规和凝血常规数据、深静脉血栓(DVT)和药品不良反应发生情况。结果:用药后两组血红蛋白和血小板计数明显下降(P<0.05),停药后恢复正常,其他各项血常规和凝血常规无明显变化。Ⅰ组发生大出血1例,Ⅱ组3例;Ⅰ组未发生DVT,Ⅱ组发生3例,两组DVT发生率比较,差异有统计学意义(P<0.05),两组均无严重药品不良反应发生。结论:利伐沙班预防DVT的发生效果良好,比低分子肝素具有更好的疗效和安全性。
Objective: To retrospectively analyze the clinical efficacy and safety of rivaroxaban against deep vein thrombosis. Methods: A total of 94 patients with lower extremity bone surgery from June 2010 to June 2013 in our hospital were divided into group Ⅰ (rivaroxaban 10 mg, po, qd) and group Ⅱ (low molecular weight heparin Injection 4 000 IU, ih, qd). The postoperative bleeding, the routine blood tests and coagulation data, the deep venous thrombosis (DVT) and adverse drug reactions were compared between the two groups before and after treatment. Results: After treatment, hemoglobin and platelet count decreased significantly in both groups (P <0.05), and returned to normal after stopping treatment. There was no significant change in other blood routine and coagulation routine. There were 1 case of hemorrhage in group Ⅰ and 3 cases in group Ⅱ. There was no DVT in group Ⅰ, 3 cases in group Ⅱ, the incidence of DVT was significant difference between the two groups (P0.05) occur. Conclusion: Rivaroxaban is effective in preventing DVT and has better curative effect and safety than low molecular weight heparin.